Arbeitsgemeinschaft Medikamentoese Tumortherapie gGmbH
Arbeitsgemeinschaft Medikamentoese Tumortherapie gGmbH is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma and Subsequent Maintenance with Elotuzumab and Lenalidomide versus Single-Agent Lenalidomide. A phase III study by DSMM (Deutsche Studiengruppe Multiples Myelom)
Sponsor Universitaetsklinikum Wuerzburg AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dosed R-CHOP
Sponsor Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin’s Lymphoma, Followed by Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy
Sponsor Fundacion Geltamo
- Start (EU)
- Latest update
- Estimated end
An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)
Sponsor GWT-Tud GmbH
- Start (EU)
- Latest update
- Estimated end
HD21 for advanced stages - Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Arbeitsgemeinschaft Medikamentoese Tumortherapie gGmbH?
The 2026-10-09 snapshot links Arbeitsgemeinschaft Medikamentoese Tumortherapie gGmbH to 5 distinct CTIS trials. Recorded services include Clinical monitoring, Project management, Regulatory services, Investigator recruitment, among 7 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Arbeitsgemeinschaft Medikamentoese Tumortherapie gGmbH?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Arbeitsgemeinschaft Medikamentoese Tumortherapie gGmbH conducted?
The linked trials record locations in 9 countries, including Austria, Germany, Spain, Denmark, Greece. These are trial locations, not confirmed office locations or countries where Arbeitsgemeinschaft Medikamentoese Tumortherapie gGmbH delivered services.
What can this page tell me about Arbeitsgemeinschaft Medikamentoese Tumortherapie gGmbH's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Arbeitsgemeinschaft Medikamentoese Tumortherapie gGmbH. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Arbeitsgemeinschaft Medikamentoese Tumortherapie gGmbH